133 related articles for article (PubMed ID: 28066808)
1. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.
Li W; Arasu V; Newitt DC; Jones EF; Wilmes L; Gibbs J; Kornak J; Joe BN; Esserman LJ; Hylton NM;
Tomography; 2016 Dec; 2(4):378-387. PubMed ID: 28066808
[TBL] [Abstract][Full Text] [Related]
2. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
Lo WC; Li W; Jones EF; Newitt DC; Kornak J; Wilmes LJ; Esserman LJ; Hylton NM
PLoS One; 2016; 11(2):e0142047. PubMed ID: 26886725
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
Hylton NM; Gatsonis CA; Rosen MA; Lehman CD; Newitt DC; Partridge SC; Bernreuter WK; Pisano ED; Morris EA; Weatherall PT; Polin SM; Newstead GM; Marques HS; Esserman LJ; Schnall MD;
Radiology; 2016 Apr; 279(1):44-55. PubMed ID: 26624971
[TBL] [Abstract][Full Text] [Related]
4. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
Arasu VA; Kim P; Li W; Strand F; McHargue C; Harnish R; Newitt DC; Jones EF; Glymour MM; Kornak J; Esserman LJ; Hylton NM;
J Breast Imaging; 2020 Aug; 2(4):352-360. PubMed ID: 32803155
[TBL] [Abstract][Full Text] [Related]
5. Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial.
Onishi N; Li W; Gibbs J; Wilmes LJ; Nguyen A; Jones EF; Arasu V; Kornak J; Joe BN; Esserman LJ; Newitt DC; Hylton NM
Tomography; 2020 Jun; 6(2):77-85. PubMed ID: 32548283
[TBL] [Abstract][Full Text] [Related]
6. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
Onishi N; Bareng TJ; Gibbs J; Li W; Price ER; Joe BN; Kornak J; Esserman LJ; Newitt DC; Hylton NM; ;
Radiol Imaging Cancer; 2023 Jul; 5(4):e220126. PubMed ID: 37505107
[TBL] [Abstract][Full Text] [Related]
7. Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer.
Musall BC; Abdelhafez AH; Adrada BE; Candelaria RP; Mohamed RMM; Boge M; Le-Petross H; Arribas E; Lane DL; Spak DA; Leung JWT; Hwang KP; Son JB; Elshafeey NA; Mahmoud HS; Wei P; Sun J; Zhang S; White JB; Ravenberg EE; Litton JK; Damodaran S; Thompson AM; Moulder SL; Yang WT; Pagel MD; Rauch GM; Ma J
J Magn Reson Imaging; 2021 Jul; 54(1):251-260. PubMed ID: 33586845
[TBL] [Abstract][Full Text] [Related]
8. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.
Hatt M; Groheux D; Martineau A; Espié M; Hindié E; Giacchetti S; de Roquancourt A; Visvikis D; Cheze-Le Rest C
J Nucl Med; 2013 Mar; 54(3):341-9. PubMed ID: 23327900
[TBL] [Abstract][Full Text] [Related]
9. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.
Jafri NF; Newitt DC; Kornak J; Esserman LJ; Joe BN; Hylton NM
J Magn Reson Imaging; 2014 Aug; 40(2):476-82. PubMed ID: 24347097
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
Santamaría G; Bargalló X; Fernández PL; Farrús B; Caparrós X; Velasco M
Radiology; 2017 Jun; 283(3):663-672. PubMed ID: 27875106
[TBL] [Abstract][Full Text] [Related]
11. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
Li W; Newitt DC; Gibbs J; Wilmes LJ; Jones EF; Arasu VA; Strand F; Onishi N; Nguyen AA; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard SA; Umphrey H; Bernreuter W; Nelson M; Church AL; Bolan P; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez-Paniagua D; Hardesty L; Brandt K; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane EP; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica A; Niell BL; Drukteinis J; Newell MS; Cohen MA; Giurescu M; Berman E; Lehman C; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau S; Chenevert T; Yau C; DeMichele A; Berry D; Esserman LJ; Hylton NM
NPJ Breast Cancer; 2020 Nov; 6(1):63. PubMed ID: 33298938
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
Magbanua MJM; Li W; Wolf DM; Yau C; Hirst GL; Swigart LB; Newitt DC; Gibbs J; Delson AL; Kalashnikova E; Aleshin A; Zimmermann B; Chien AJ; Tripathy D; Esserman L; Hylton N; van 't Veer L
NPJ Breast Cancer; 2021 Mar; 7(1):32. PubMed ID: 33767190
[TBL] [Abstract][Full Text] [Related]
13. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI.
Panthi B; Adrada BE; Candelaria RP; Guirguis MS; Yam C; Boge M; Chen H; Hunt KK; Huo L; Hwang KP; Korkut A; Lane DL; Le-Petross HC; Leung JWT; Litton JK; Mohamed RM; Musall BC; Pashapoor S; Patel MM; Perez F; Son JB; Thompson A; Valero V; Wei P; White J; Xu Z; Pinsky L; Tripathy D; Yang W; Ma J; Rauch GM
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831368
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
16. MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.
van Ramshorst MS; Loo CE; Groen EJ; Winter-Warnars GH; Wesseling J; van Duijnhoven F; Peeters MTV; Sonke GS
Breast Cancer Res Treat; 2017 Jul; 164(1):99-106. PubMed ID: 28432515
[TBL] [Abstract][Full Text] [Related]
17. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.
Olshen A; Wolf D; Jones EF; Newitt D; van ‘t Veer LJ; Yau C; Esserman L; Wulfkuhle JD; Gallagher RI; Singer L; Petricoin EF; Hylton N; Park CC
J Med Imaging (Bellingham); 2018 Jan; 5(1):011014. PubMed ID: 29296631
[TBL] [Abstract][Full Text] [Related]
18. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
[TBL] [Abstract][Full Text] [Related]
19. Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Graeser M; Schrading S; Gluz O; Strobel K; Würstlein R; Kümmel S; Schumacher C; Grischke EM; Forstbauer H; Braun M; Christgen M; Adams J; Nitzsche H; Just M; Fischer HH; Aktas B; Potenberg J; von Schumann R; Kolberg-Liedtke C; Harbeck N; Kuhl CK; Nitz U
Int J Cancer; 2021 May; 148(10):2614-2627. PubMed ID: 33533487
[TBL] [Abstract][Full Text] [Related]
20. Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment.
Bufi E; Belli P; Di Matteo M; Terribile D; Franceschini G; Nardone L; Petrone G; Bonomo L
Eur J Radiol; 2014 Sep; 83(9):1631-8. PubMed ID: 24938669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
